VRTX241004P477500
- 9.60
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
Vertex Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)
DBS Initiates Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $502
Wolfe Research Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $518
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $518 From $576, Maintains Outperform Rating
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Vertex Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $474
Maintaining Hold Rating on Vertex Pharmaceuticals Amidst LSR Trial Uncertainties
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target
Vertex Pharmaceuticals (VRTX) Gets a Hold From RBC Capital
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals: A Cautious Hold Amidst Mixed Financial Signals and Pipeline Uncertainty